News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitcoin adoption ‘booming’ while price chops: Which metrics matter most?2SEC approval sought for JitoSOL Solana-based liquid staking token ETF3Bitget UEX Daily｜Positive Progress in U.S.-Iran Talks; Nvidia Plunges Over 5%; Dell Guidance Beats Expectations (February 27, 2026)
Egrag Crypto to XRP Investors: Just Do It “You Must Be Buying, Not Crying”
TimesTabloid·2026/02/27 12:33
The sports IP industry can’t defend itself against AI without blockchain
Cointelegraph·2026/02/27 12:33
Japanese Yen surrenders much of its initial advance versus the USD prior to the release of US PPI figures
101 finance·2026/02/27 12:27
Tether says it has frozen $4.2 billion of its stablecoin over crime links
101 finance·2026/02/27 12:18
AMT's Lagging Performance Compared to the Dow: Is Perfection Already Reflected in the Price?
101 finance·2026/02/27 12:07
1 Underappreciated Stock Worth Your Attention and 2 Encountering Obstacles
101 finance·2026/02/27 12:00
Ashtead: The Expectation Gap Between a Strong Business and a Fairly Priced One
101 finance·2026/02/27 11:57
AlzChem's 2025 Print vs. The Priced-In Expectation Gap
101 finance·2026/02/27 11:54
US stock futures falter on AI jitters, Nasdaq braces for steep monthly fall
101 finance·2026/02/27 11:54
Flash
12:24
ROMAN DBDR ACQUISITION CORP II recently disclosed that, through a price-based earnout mechanism, the company’s transaction value is expected to achieve significant growth.Specifically, if the company's stock price reaches the preset target, the transaction value may increase by an additional $450 million, bringing the total value up to a maximum of $1.3 billion. This profit target mechanism is designed to incentivize the company's management to improve performance and drive the stock price higher. As market expectations for the company's future development heat up, investors are closely monitoring its stock price performance and the potential for value realization.
12:24
TransMedics Group (TMDX) recently provided additional disclosure regarding the specific impact of the release of the deferred tax asset valuation allowance in relation to its previously announced fourth-quarter financial results.The company stated that the release of this valuation allowance resulted in a significant adjustment to the carrying value of its deferred income tax assets, thereby having a substantial impact on the relevant items in the fourth quarter financial statements. TransMedics emphasized that this adjustment will not have a direct impact on the company's cash flow or business operations, but it will help more accurately reflect the actual value of its tax assets.
12:24
Strategy (MSTR.US) becomes the most shorted stock in the US market as arbitrage trading emergesHowever, some analysts have pointed out that this position layout does not necessarily reflect investors' expectations of a continued decline in stock prices.
News